Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

483
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
483
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

697
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
697
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

1.3K
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
1.3K
Cancer Survival Analysis01:21

Cancer Survival Analysis

820
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
820
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

310
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
310
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

707
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
707

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative malnutrition is associated with suppressed intratumoral T cell function and distinct tumor-associated microbiota in colorectal cancer: a prospective pilot study.

Frontiers in nutrition·2026
Same author

Cannabizetol, a Novel Cannabinoid: Chemical Synthesis, Anti-inflammatory Activity and Extraction from <i>Cannabis sativa</i> L.

Journal of natural products·2025
Same author

Rotational Motion in Bispidines: A Conformational Study.

Organic letters·2025
Same author

The Ten Dietary Commandments for Patients with Irritable Bowel Syndrome: A Narrative Review with Pragmatic Indications.

Nutrients·2025
Same author

Multiple bursts of speciation in Madagascar's endangered lemurs.

Nature communications·2025
Same author

Close encounters of the friendly kind: pacific between-group interactions in primates.

Biological reviews of the Cambridge Philosophical Society·2025

Related Experiment Video

Updated: Mar 22, 2026

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.6K

A Bayesian hierarchical surrogate outcome model for multiple sclerosis.

Luca Pozzi1, Heinz Schmidli2, David I Ohlssen3

  • 1Division of Biostatistics, University of California Berkeley, Berkeley, 94720-7358, CA, USA.

Pharmaceutical Statistics
|April 11, 2016
PubMed
Summary
This summary is machine-generated.

Developing new multiple sclerosis (MS) treatments uses surrogate outcomes. This study created a Bayesian model combining MRI lesions and relapses to better predict disability progression in MS clinical trials.

Keywords:
Bayesian hierarchical modelingclinical trialsdrug development decisionsmultivariate meta-analysissurrogate outcome

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

3.0K

Related Experiment Videos

Last Updated: Mar 22, 2026

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.6K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

3.0K

Area of Science:

  • Neurology
  • Clinical Research Methodology
  • Biostatistics

Background:

  • Multiple sclerosis (MS) drug development faces challenges with long-term disability endpoints.
  • Early MS stages are monitored using clinical relapses and MRI lesion counts as surrogate outcomes.
  • Existing research has explored MRI lesions and relapses as surrogates for disability progression.

Purpose of the Study:

  • To develop a novel Bayesian three-level model for multiple sclerosis (MS) clinical trials.
  • To integrate MRI lesion counts and clinical relapses as surrogate outcomes for disability progression.
  • To improve the efficiency and decision-making in MS drug development.

Main Methods:

  • A Bayesian three-level model was developed to accommodate MRI lesions, relapses, and disability endpoints.
  • The model accounts for errors in treatment effect estimations.
  • Weighted regression analyses were used to examine surrogate endpoint roles.

Main Results:

  • A study-level surrogate outcome model was created by combining treatment effects from MRI lesion counts and clinical relapses.
  • This model predicts treatment effects on disability progression.
  • The model offers a more sensitive measure for early-stage MS trials.

Conclusions:

  • The proposed Bayesian model effectively integrates multiple surrogate outcomes for MS clinical trials.
  • This approach supports better decision-making in the development of novel MS therapies.
  • The model provides a framework for future validation in MS research.